DNA dosimetry following carcinogen exposure using accelerator mass spectrometry and 32P-postlabeling.
Felton
J S
JS
Biomedical Sciences Division, University of California, Lawrence Livermore National Laboratory, Livermore 94550.
Turteltaub
K W
KW
Gledhill
B L
BL
Vogel
J S
JS
Buonarati
M H
MH
Davis
J C
JC
D000818:Animals; D001665:Binding Sites; D002273:Carcinogens / Q000008:administration & dosage* / Q000378:metabolism / Q000633:toxicity; D004247:DNA / Q000032:analysis / Q000187:drug effects* / Q000378:metabolism; D004249:DNA Damage; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000378:metabolism / Q000633:toxicity; D013058:Mass Spectrometry; D051379:Mice; D010761:Phosphorus Radioisotopes; D011810:Quinoxalines / Q000008:administration & dosage / Q000378:metabolism / Q000633:toxicity
D002273:Carcinogens; D007093:Imidazoles; D010761:Phosphorus Radioisotopes; D011810:Quinoxalines; C036990:2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline; D004247:DNA; C049584:2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine